[go: up one dir, main page]

WO2007125398A3 - : sulfonamide compounds as antagonists of the n-type calcium channel - Google Patents

: sulfonamide compounds as antagonists of the n-type calcium channel Download PDF

Info

Publication number
WO2007125398A3
WO2007125398A3 PCT/IB2007/001084 IB2007001084W WO2007125398A3 WO 2007125398 A3 WO2007125398 A3 WO 2007125398A3 IB 2007001084 W IB2007001084 W IB 2007001084W WO 2007125398 A3 WO2007125398 A3 WO 2007125398A3
Authority
WO
WIPO (PCT)
Prior art keywords
calcium channel
type calcium
antagonists
sulfonamide compounds
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2007/001084
Other languages
French (fr)
Other versions
WO2007125398A2 (en
Inventor
Tadashi Inoue
Hirohide Noguchi
Isao Sakurada
Miyuki Tatsuta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp Belgium
Pfizer Japan Inc
Pfizer Corp SRL
Original Assignee
Pfizer Corp Belgium
Pfizer Japan Inc
Pfizer Corp SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp Belgium, Pfizer Japan Inc, Pfizer Corp SRL filed Critical Pfizer Corp Belgium
Publication of WO2007125398A2 publication Critical patent/WO2007125398A2/en
Publication of WO2007125398A3 publication Critical patent/WO2007125398A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention provides the compounds of formula (I): or a pharmaceutically acceptable salt thereof, wherein Q is CH2 or the like; Z1 is CRa or the like; Z2 is CRb or the like; R1 and R2 are each independently hydrogen or the like, Ra, Rb, R3, R4 and R5 are each independently hydrogen or the like and n is 1 or the like. These compounds are useful for the treatment of disease conditions caused by overactivation of N type calcium channel such as pain or the like in mammalian. This invention also provides a pharmaceutical composition comprising the above compound.
PCT/IB2007/001084 2006-04-27 2007-04-17 : sulfonamide compounds as antagonists of the n-type calcium channel Ceased WO2007125398A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79584306P 2006-04-27 2006-04-27
US60/795,843 2006-04-27

Publications (2)

Publication Number Publication Date
WO2007125398A2 WO2007125398A2 (en) 2007-11-08
WO2007125398A3 true WO2007125398A3 (en) 2008-03-06

Family

ID=38462474

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2007/001084 Ceased WO2007125398A2 (en) 2006-04-27 2007-04-17 : sulfonamide compounds as antagonists of the n-type calcium channel

Country Status (1)

Country Link
WO (1) WO2007125398A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8044069B2 (en) 2008-10-02 2011-10-25 Abbott Laboratories Compounds as calcium channel blockers
WO2010091721A1 (en) * 2009-02-11 2010-08-19 Glaxo Group Limited 3 -substituted 1-arylsulfonylpiperidine derivatives for the treatment of pain
BRPI1016130A2 (en) 2009-04-02 2017-03-28 Shionogi & Co compound, pharmaceutical composition, and methods for treating or preventing a disorder and condition.
US8815869B2 (en) 2010-03-18 2014-08-26 Abbvie Inc. Lactam acetamides as calcium channel blockers
CA2798831A1 (en) 2010-05-11 2011-11-17 Pfizer Inc. Morpholine compounds as mineralocorticoid receptor antagonists
BR112016023860A2 (en) * 2014-04-14 2017-08-15 Gruenenthal Gmbh heteroaryl substituted heterocyclyl sulfones
EA032638B1 (en) * 2014-04-14 2019-06-28 Грюненталь Гмбх Aryl substituted heterocyclyl sulfones
TW201726128A (en) * 2015-10-08 2017-08-01 歌林達有限公司 Pyrazolyl substituted tetrahydropyranylsulfones
TW201718557A (en) * 2015-10-08 2017-06-01 歌林達有限公司 Pyrazolyl substituted tetrahydropyranylsulfones

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2722531A (en) * 1955-11-01 Substituted oxazoljbines and process
WO2005068448A1 (en) * 2003-08-29 2005-07-28 Ionix Pharmaceuticals Limited Sulfonamides antagonising n-type calcium channels
WO2005118538A2 (en) * 2004-04-20 2005-12-15 Amgen, Inc. Arylsulfonamides and uses as hydroxysteroid dehydrogenase
WO2007057768A2 (en) * 2005-11-18 2007-05-24 Pfizer Products Inc. Sulfonyl derivatives

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2722531A (en) * 1955-11-01 Substituted oxazoljbines and process
WO2005068448A1 (en) * 2003-08-29 2005-07-28 Ionix Pharmaceuticals Limited Sulfonamides antagonising n-type calcium channels
WO2005118538A2 (en) * 2004-04-20 2005-12-15 Amgen, Inc. Arylsulfonamides and uses as hydroxysteroid dehydrogenase
WO2007057768A2 (en) * 2005-11-18 2007-05-24 Pfizer Products Inc. Sulfonyl derivatives

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE REGISTRY [online] 1 August 2004 (2004-08-01), XP002450768, Database accession no. 720000-00-0 *
FRITZ MICHEEL, SIEGFRIED THOMAS: "Eine neue Peptid-Synthese", CHEMISCHE BERICHTE, vol. 90, no. 12, 1957, pages 2906 - 2909, XP002450766 *
HOMER ADKINS AND HARRY L. COONRADT: "The Selective Hydrogenation of Derivatives of Pyrrole, Indole, Carbazole and Acridine", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 63, no. 6, 1941, pages 1563 - 1570, XP002450765 *
SCHIMMELSCHMIDT K ET AL: "Darstellung und Umsetzungen der 2-amino-aethylthioschwefelsaeure", CHEMISCHE BERICHTE, VERLAG CHEMIE GMBH. WEINHEIM, DE, vol. 96, no. 1, 1963, pages 38 - 47, XP002220236, ISSN: 0009-2940 *
SCHLUMMER BJORN ET AL: "Bronsted acid-catalyzed intramolecular hydroamination of protected alkenylamines. Synthesis of pyrrolidines and piperidines", ORGANIC LETTERS, vol. 4, no. 9, 2 May 2002 (2002-05-02), pages 1471 - 1474, XP002450763, ISSN: 1523-7060 *
W. E. CASS: "Sulfanilyl Pyrrolidine and Pyrroline", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 62, no. 11, 1940, pages 3255 - 3256, XP002450764 *

Also Published As

Publication number Publication date
WO2007125398A2 (en) 2007-11-08

Similar Documents

Publication Publication Date Title
WO2007125398A3 (en) : sulfonamide compounds as antagonists of the n-type calcium channel
EA201000050A1 (en) SUBSTITUTED BICYCLOPLASTIC COMPOUNDS
EA200801998A1 (en) ПИРДДИН [3,4-b] ПИРАЗИНОНЫ
EA201001669A1 (en) SUBSTITUTED PYRIMIDIN-5-CARBOXAMIDES 281
WO2008012635A3 (en) Amine derivatives useful as anticancer agents
MX2009004900A (en) Thiazole and oxazole-substituted arylamides.
TW200635899A (en) Chemical compounds
EA201101672A1 (en) SUBSTITUTED DERIVATIVES OF AMINOISAL ACID AS NEPRILISIN INHIBITORS
MX2007005694A (en) Novel betulin derivatives, preparation thereof and use thereof.
BG108650A (en) Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease
MY151295A (en) Pyrimidyl indoline compound
EA200700099A1 (en) PYRIDINE DERIVATIVES
WO2007146758A3 (en) Novel mch receptor antagonists
EA200802007A1 (en) COMPOUNDS POTENTIATING AMPA RECEPTOR AND APPLICATION OF THE SPECIFIED COMPOUNDS IN MEDICINE
SE0302760D0 (en) New compounds
WO2004089366A8 (en) Bicyclic compounds as nr2b receptor antagonists
MX2008001606A (en) Substituted piperazines as metabotropic glutamate receptor antagonists.
MX2012001160A (en) Sphingosine-1-phosphate receptor agonists.
DK1725536T3 (en) Imidazoline derivatives with CB1 antagonistic activity
TW200626158A (en) Naphthaline derivatives
WO2005075450A3 (en) Spiro-benzodioxoles and their use as cb1 antagonists
TW200716547A (en) Piperidin-4-yl-amide derivatives
TW200806321A (en) New therapeutic combinations for the treatment or prevention of psychotic disorders
SE0303480D0 (en) Benzofuranes
MX2007006387A (en) 3-substituted pyridine derivatives as h3 antagonists.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07734402

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07734402

Country of ref document: EP

Kind code of ref document: A2